Paradigm raises $1.5m to push global sales expansion of eye imager:
This article was originally published in Clinica
Diagnostic systems developer Paradigm Medical Industries is to ramp up its global sales and marketing efforts, using the $1.5m it raised from a recent convertible note sale. The company will focus particularly on its lead product, the P60 Ultrasound BioMicroscope (UBM), a fourth-generation ultrasound device for imaging conditions of the eye. The system is approved in the US, various European and Pacific Rim countries and, most recently, in Canada (see Clinica No 1196, p 18). The proceeds from the note sale will also go towards building up the Salt Lake City, Utah firm's inventory.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.